| Literature DB >> 31771983 |
Yanchun Peng1,2, Tao Dong3,2, Megat Abd Hamid1,2, Huw Colin-York2, Nasullah Khalid-Alham4,5, Molly Browne6, Lucia Cerundolo6, Ji-Li Chen2, Xuan Yao1,2, Samara Rosendo-Machado2, Craig Waugh7, David Maldonado-Perez6, Emma Bowes6, Clare Verrill5,6, Vincenzo Cerundolo1,2, Christopher P Conlon1, Marco Fritzsche2,8.
Abstract
Enrichment of CD103+ tumor-infiltrating T lymphocytes (TIL) is associated with improved outcomes in patients. However, the characteristics of human CD103+ cytotoxic CD8+ T cells (CTL) and their role in tumor control remain unclear. We investigated the features and antitumor mechanisms of CD103+ CTLs by assessing T-cell receptor (TCR)-matched CD103+ and CD103- cancer-specific CTL immunity in vitro and its immunophenotype ex vivo Interestingly, we found that differentiated CD103+ cancer-specific CTLs expressed the active form of TGFβ1 to continually self-regulate CD103 expression, without relying on external TGFβ1-producing cells. The presence of CD103 on CTLs improved TCR antigen sensitivity, which enabled faster cancer recognition and rapid antitumor cytotoxicity. These CD103+ CTLs had elevated energetic potential and faster migration capacity. However, they had increased inhibitory receptor coexpression and elevated T-cell apoptosis following prolonged cancer exposure. Our data provide fundamental insights into the properties of matured human CD103+ cancer-specific CTLs, which could have important implications for future designs of tissue-localized cancer immunotherapy strategies. ©2019 American Association for Cancer Research.Entities:
Mesh:
Substances:
Year: 2019 PMID: 31771983 PMCID: PMC7611226 DOI: 10.1158/2326-6066.CIR-19-0554
Source DB: PubMed Journal: Cancer Immunol Res ISSN: 2326-6066 Impact factor: 11.151